About 900 reports

## SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES

  • Drug Development
  • Pharmaceutical
  • Biopharmaceutical
  • Clinical Trial
  • United States
  • APAC
  • Drug Approval
  • Chronic Disease Prevalence

TABLE ## IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

  • Pharmaceutical
  • Healthcare
  • Environmental Monitoring
  • World
  • United States
  • Europe
  • North America
  • Pharmaceutical R&D Expenditure
  • Pharmaceutical Production

For example, on Dec. 2020, Clover Biopharmaceuticals, a China-based biotechnology company, announced positive clinical data from its Phase ## trial demonstrating that its protein-based COVID-## S-Trimer vaccine candidates in combination with adjuvants from either GSK induce strong immune responses, including neutralizing antibodies and cell-mediated immunity, as well as favorable safety and tolerability profiles in ## adult and elderly participants.

  • Proteomics
  • APAC
  • Health Expenditure
  • Direct Sales

For example, on Dec. 2020, Clover Biopharmaceuticals, a China-based biotechnology company, announced positive clinical data from its Phase ## trial demonstrating that its protein-based COVID-## S-Trimer vaccine candidates in combination with adjuvants from either GSK induce strong immune responses, including neutralizing antibodies and cell-mediated immunity, as well as favorable safety and tolerability profiles in ## adult and elderly participants.

  • Proteomics
  • World
  • APAC
  • Europe
  • Middle East
  • Health Expenditure
  • Final Consumption Expenditures

In 2020, Amgen and Adaptive Biotechnologies (Seattle, United States) are partnering to combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-## to potentially prevent or treat COVID-##.

  • Healthcare
  • World
  • APAC
  • Health Expenditure
  • Drug Approval

published in Nature Reviews Immunology 2020, aluminum-based vaccine adjuvants offer a glide path to induce high levels of neutralizing antibody, which is increasingly being recognized as a cornerstone of the protection afforded by COVID-## vaccines.

  • Vaccine
  • World
  • Health Expenditure
  • Vaccination Coverage

Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited, and Orthosera Kft. The global convalescent plasma therapy market is expected to grow from $0.026 billion in 2020 to $0.028 billion in 2021 at a compound annual...

  • Infectious Disease
  • World
  • Middle East
  • India
  • United States
  • APAC
  • Mortality Rate
  • Drug Approval

“Hemophilia A - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Hemophilia A pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and...

  • Blood Disease
  • World

Overview “Alphanate - Drug Insight and Market Forecast – 2030” report outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Alphanate in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan,...

  • Clinical Trial
  • Hospital
  • Blood Disease
  • Europe
  • Japan
  • World
  • Spain
  • France
  • Germany
  • Italy
  • United Kingdom
  • Health Expenditure
  • Medicine Use

Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited, and Orthosera Kft. The global convalescent plasma therapy market is expected to grow from $20.3 million in 2019 to $26.4 million by the end of 2020 at a compound...

  • Infectious Disease
  • World
  • Mortality Rate
  • Drug Approval

Abstract: According to the new updated study on COVID-19 Vaccines by Global Industry Analysts (GIA), approximately 53% of world population will be fully vaccinated by the end of the year 2021. This figure is expected to increase to 81% by the year 2022. The rapid vaccination programmes launched around the world...

  • Vaccine
  • Infectious Disease
  • World
  • India
  • United States
  • United Kingdom
  • Vaccination Coverage
  • Cause-Specific Mortality Rate

This test is used for the qualitative detection of the neutralizing antibodies in patients who have recovered from novel coronavirus pneumonia or those who have been vaccinated.

  • Clinical Microbiology Testing
  • World
  • China
  • United States
  • North America
  • APAC
  • Europe
  • Infectious Disease Incidence
  • Health Expenditure

The company partnered with Adagio to manufacture and commercialize a broadly neutralizing antibody for India and select emerging markets.

  • Biopharmaceutical
  • Monoclonal Antibody
  • World
  • United States
  • North America
  • Europe
  • APAC
  • Biosimilar Penetration Rate
  • Drug Approval

Upcoming Vaccine Technologies for Infectious Diseases Vaccine Delivery platforms: This section covers various nanoparticle-based vaccine delivery platforms such as nanoparticles of biological (self-assembling proteins) and non-biological origin ( inorganic and polymeric). The biological nanoparticles subsection overlaps...

  • Vaccine
  • Gene Therapy
  • Nanotechnology-Based Drug Delivery
  • Injectable Delivery
  • Nanoparticle

Different lateral flow assay kits are launched into market to detect the level of neutralizing antibody against SARS-CoV-## in serum, plasma, and whole blood samples.

  • Point Of Care Testing
  • World
  • HIV AIDS Prevalence
  • HIV Incidence

Table ##: cPass SARS-CoV-## Neutralization Antibody Detection Kit - Product Description

  • Infectious Disease
  • Clinical Trial
  • World
  • India
  • Zhejiang
  • Pneumonia Prevalence
  • Direct Sales

IIBR is making advanced R&D efforts in developing the vaccine based on an engineered virus and monoclonal neutralizing antibodies treatment for the SARS-Cov-## virus.

  • Vaccine
  • Infectious Disease
  • World
  • Europe
  • North America
  • Latin America
  • Mortality Rate
  • Cause-Specific Mortality Rate

The trial is designed to identify an immune response, characterized by hemagglutination-inhibiting (HAI) and neutralizing antibodies, that is similar to or better than Fluzone HD

  • Infectious Disease
  • Vaccine
  • World
  • APAC
  • Health Expenditure
  • Vaccination Coverage

Table ##: SARS-CoV-## Neutralizing Antibody Test (Immuno-COV) - Product Status

  • Infectious Disease
  • Clinical Trial
  • World
  • Canada
  • China
  • India
  • South Africa
  • Beijing Municipality
  • West Virginia
  • Mohave County
  • Medical Technology Density
  • Medical Devices Sales

The major finding of the study, Herpes Simplex Virus ## (HSV-##) ##ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-## Infection in the Absence of Neutralizing Antibody in HSV-## gB T Cell Receptor-Specific Transgenic Mice," found that the company s RVX## vaccine candidate used to immunize a unique mouse line (does not generate much of a neutralizing antibody response to the virus) was shown to provide highly protective immunity and prevent herpes-associated neovascularization.

  • Drug Development
  • World
  • Manufacturing Output
  • Medicine Use

The company developed its proprietary structure inspired design platform that creates novel AAV capsids with improved characteristics including potency, tissue tropism, and ability to evade pre -existing neutralizing antibodies.

  • Neurological Disorder
  • Drug Development
  • World
  • Drug Approval
  • Mortality Rate

High-titer neutralizing antibodies

  • Pharmaceutical
  • Injectable Delivery
  • Healthcare
  • Glass
  • Blood Disease
  • Infectious Disease
  • Biopharmaceutical
  • Vaccine
  • World
  • Europe
  • United States
  • North America
  • APAC
  • South America
  • Health Expenditure
  • Biosimilar Penetration Rate

The company developed its proprietary structure inspired design platform that creates novel AAV capsids with improved characteristics including potency, tissue tropism, and ability to evade pre -existing neutralizing antibodies.

  • Neurological Disorder
  • Drug Development
  • World
  • Health Provider Density
  • Drug Approval

Neutralization Antibody Assessment

  • Drug Development
  • Pharmaceutical
  • Biotechnology
  • Nanobiotechnology
  • United States
  • Europe
  • APAC
  • North America
  • Final Consumption Expenditures
  • Pharmaceutical R&D Expenditure

High-titer neutralizing antibodies

  • Pharmaceutical
  • Injectable Delivery
  • Pharmacy
  • Biopharmaceutical
  • Infectious Disease
  • Packaging Machinery
  • APAC
  • North America
  • Europe
  • Health Expenditure
  • Infectious Disease Mortality

• They will use their expertise to identify fully human neutralizing antibodies targeting SARS-CoV-## as potential prophylactics or therapies for COVID-##.

  • Infectious Disease
  • Clinical Trial
  • Japan
  • Prescription Drug Sales
  • Mortality Rate

High-titer neutralizing antibodies

  • Infectious Disease
  • Vaccine
  • World
  • Drug Approval
  • Infectious Disease Mortality

Neutralizing antibodies against live SARS-CoV-## were all negative at day ##, and increased moderately at day ##, peaking at ## days post-vaccination.

  • Clinical Trial
  • Epidemiology
  • United States
  • Brazil
  • India
  • Infectious Disease Mortality
  • Prescription Drug Sales

Jecho Biopharmaceuticals is also developing bispecific and neutralizing antibodies to prevent COVID-##.

  • Chronic Disease
  • Blood Disease
  • Drug Development
  • World
  • Japan
  • China
  • Jiangsu
  • Drug Approval
  • Pharmaceutical Registrations

The company devel oped its propri etary structure inspired design plat form that creates novel AAV capsids with im proved characteristics including pot ency, tissue tropism, a nd ability to evade pre-existing neutralizing antibodies.

  • Neurological Disorder
  • World
  • Drug Approval
  • Dropout Rate